MA49278A - Oligonucléotides antisens pour moduler l'expression de htra1 - Google Patents

Oligonucléotides antisens pour moduler l'expression de htra1

Info

Publication number: MA49278A
Authority: MA; Morocco
Prior art keywords: antisen; htra1; oligonucleotides; modulate; expression
Prior art date: 2017-06-01

Application number

MA049278A

Other languages

English (en)

Inventor

Marco Berrera

Andreas Dieckmann

Peter Hagedorn

Heidi Rye Hudlebusch

Roberto Iacone

Susanne Kammler

S Ren Ottosen

Lykke Pedersen

Nchez Rub N Alvarez S

Sindri Traustason

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-06-01

Filing date

2018-05-30

Publication date

2020-04-08

2018-05-30 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2020-04-08 Publication of MA49278A publication Critical patent/MA49278A/fr

Links

101001041393 Homo sapiens Serine protease HTRA1 Proteins 0.000 title 1
108091034117 Oligonucleotide Proteins 0.000 title 1
102100021119 Serine protease HTRA1 Human genes 0.000 title 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21108—HtrA2 peptidase (3.4.21.108)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Epidemiology (AREA)
Virology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

MA049278A 2017-06-01 2018-05-30 Oligonucléotides antisens pour moduler l'expression de htra1 MA49278A (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP17173964		2017-06-01
EP17209535		2017-12-21
EP17209407		2017-12-21

Publications (1)

Publication Number	Publication Date
MA49278A true MA49278A (fr)	2020-04-08

Family

ID=62245334

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA049278A MA49278A (fr)	2017-06-01	2018-05-30	Oligonucléotides antisens pour moduler l'expression de htra1

Country Status (19)

Country	Link
US (3)	US20190055564A1 (fr)
EP (1)	EP3630976A1 (fr)
JP (1)	JP7169995B2 (fr)
KR (1)	KR20200015608A (fr)
CN (1)	CN110691849A (fr)
AU (1)	AU2018277219A1 (fr)
BR (1)	BR112019025290A2 (fr)
CA (1)	CA3062590A1 (fr)
CL (1)	CL2019003337A1 (fr)
CO (1)	CO2019013317A2 (fr)
CR (1)	CR20190543A (fr)
IL (1)	IL271039A (fr)
MA (1)	MA49278A (fr)
MX (1)	MX2019014187A (fr)
PE (1)	PE20191845A1 (fr)
PH (1)	PH12019502636A1 (fr)
RU (1)	RU2019143004A (fr)
TW (1)	TW201907008A (fr)
WO (1)	WO2018220034A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3478839A1 (fr)	2016-07-01	2019-05-08	H. Hoffnabb-La Roche Ag	Oligonucléotides antisens pour la modulation de l'expression de htra1
CA3090901A1 (fr)	2018-02-12	2019-08-15	Ionis Pharmaceuticals, Inc.	Composes modifies et leurs utilisations
WO2022039565A1 (fr) *	2020-08-20	2022-02-24	(주)지놈오피니언	Biomarqueur pour le diagnostic d'une dégénérescence maculaire liée à l'âge et utilisation associée
CA3199951A1 (fr) *	2020-10-30	2022-05-05	Hideaki Hara	Modulateur de gdf15 destine a etre utilise dans l'inhibition de la fibrose des tissus oculaires

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3756313B2 (ja)	1997-03-07	2006-03-15	武今西	新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
CA2303299C (fr)	1997-09-12	2016-02-23	Exiqon A/S	Analogues d'oligonucleotides
WO2000008134A2 (fr) *	1998-08-03	2000-02-17	Novartis Ag	SERINE PROTEASE DE HtrA HUMAINE
PT1152009E (pt)	1999-02-12	2005-03-31	Sankyo Co	Novos analogos de nucleosidos e oligonucleotidos
NZ514348A (en)	1999-05-04	2004-05-28	Exiqon As	L-ribo-LNA analogues
US6617442B1 (en)	1999-09-30	2003-09-09	Isis Pharmaceuticals, Inc.	Human Rnase H1 and oligonucleotide compositions thereof
US9045518B2 (en)	2002-11-18	2015-06-02	Santaris Pharma A/S	Amino-LNA, thio-LNA and alpha-L-oxy-LN
EP1888083B1 (fr) *	2005-05-24	2011-12-28	Isis Pharmaceuticals, Inc.	Compositions et utilisations dans la lmw-ptpase
WO2007031091A2 (fr)	2005-09-15	2007-03-22	Santaris Pharma A/S	Composes antagonistes d'arn de modulation de l'expression de p21 ras
ES2351674T3 (es)	2006-01-27	2011-02-09	Isis Pharmaceuticals, Inc.	Análogos de ácidos nucleicos bicíclicos modificados en la posición 6.
US7666854B2 (en)	2006-05-11	2010-02-23	Isis Pharmaceuticals, Inc.	Bis-modified bicyclic nucleic acid analogs
CA2651453C (fr)	2006-05-11	2014-10-14	Isis Pharmaceuticals, Inc.	Analogues d'acides nucleiques bicycliques modifies en 5'
JP2009544317A (ja)	2006-07-26	2009-12-17	イェールユニバーシティー	加齢性黄斑変性の診断および治療
US20100166743A1 (en) *	2006-10-06	2010-07-01	University Of Utah Research Foundation	Method of detecting ocular diseases and pathologic conditions and treatment of same
EP2170917B1 (fr)	2007-05-30	2012-06-27	Isis Pharmaceuticals, Inc.	Analogues d'acides nucléiques bicycliques pontés par aminométhylène n-substitué
EP2173760B2 (fr)	2007-06-08	2015-11-04	Isis Pharmaceuticals, Inc.	Analogues d'acide nucléique bicyclique carbocylique
TW200911290A (en) *	2007-07-02	2009-03-16	Alcon Res Ltd	RNAI-mediated inhibition of HTRA1 for treatment of macular degeneration
EP2176280B2 (fr)	2007-07-05	2015-06-24	Isis Pharmaceuticals, Inc.	Analogues d'acides nucléiques bicycliques disubstitués en position 6
US20100324154A1 (en) *	2007-11-01	2010-12-23	Hageman Gregory S	Assessing susceptibility to vascular disorders
WO2009067647A1 (fr)	2007-11-21	2009-05-28	Isis Pharmaceuticals, Inc.	Analogues d'acide nucléique alpha-l-bicyclique carbocyclique
US8501805B2 (en)	2008-09-24	2013-08-06	Isis Pharmaceuticals, Inc.	Substituted alpha-L-bicyclic nucleosides
US9012421B2 (en)	2009-08-06	2015-04-21	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexose nucleic acid analogs
WO2011156202A1 (fr)	2010-06-08	2011-12-15	Isis Pharmaceuticals, Inc.	2'‑amino- et 2'‑thio-nucléosides bicycliques substitués et composés oligomères préparés à partir de ces derniers
FR2965278B1 (fr) *	2010-09-23	2014-10-10	Univ Caen Basse Normandie	Procede d'obtention in vitro ou ex vivo de chondrocytes et leurs utilisations
SG11201401314PA (en)	2011-09-07	2014-09-26	Marina Biotech Inc	Synthesis and uses of nucleic acid compounds with conformationally restricted monomers
EP2850092B1 (fr)	2012-04-09	2017-03-01	Ionis Pharmaceuticals, Inc.	Analogues tricycliques d'acide nucléique
WO2013173637A1 (fr) *	2012-05-16	2013-11-21	Rana Therapeutics, Inc.	Compositions et méthodes pour moduler l'expression génique
SG10201804331TA (en)	2012-11-15	2018-07-30	Roche Innovation Ct Copenhagen As	Oligonucleotide conjugates
WO2018087200A1 (fr) *	2016-11-11	2018-05-17	Roche Innovation Center Copenhagen A/S	Capture et détection d'oligonucléotides thérapeutiques

2018
- 2018-05-29 US US15/991,326 patent/US20190055564A1/en not_active Abandoned
- 2018-05-30 KR KR1020197038723A patent/KR20200015608A/ko not_active Withdrawn
- 2018-05-30 EP EP18727310.7A patent/EP3630976A1/fr not_active Withdrawn
- 2018-05-30 CR CR20190543A patent/CR20190543A/es unknown
- 2018-05-30 MA MA049278A patent/MA49278A/fr unknown
- 2018-05-30 WO PCT/EP2018/064221 patent/WO2018220034A1/fr not_active Ceased
- 2018-05-30 BR BR112019025290-8A patent/BR112019025290A2/pt not_active Application Discontinuation
- 2018-05-30 MX MX2019014187A patent/MX2019014187A/es unknown
- 2018-05-30 CA CA3062590A patent/CA3062590A1/fr not_active Abandoned
- 2018-05-30 RU RU2019143004A patent/RU2019143004A/ru unknown
- 2018-05-30 JP JP2019566236A patent/JP7169995B2/ja active Active
- 2018-05-30 PE PE2019002473A patent/PE20191845A1/es unknown
- 2018-05-30 CN CN201880036053.5A patent/CN110691849A/zh active Pending
- 2018-05-30 AU AU2018277219A patent/AU2018277219A1/en not_active Abandoned
- 2018-05-31 TW TW107118609A patent/TW201907008A/zh unknown
2019
- 2019-10-28 US US16/665,317 patent/US20200157546A1/en not_active Abandoned
- 2019-11-20 CL CL2019003337A patent/CL2019003337A1/es unknown
- 2019-11-22 PH PH12019502636A patent/PH12019502636A1/en unknown
- 2019-11-27 CO CONC2019/0013317A patent/CO2019013317A2/es unknown
- 2019-11-28 IL IL271039A patent/IL271039A/en unknown
2021
- 2021-08-17 US US17/404,989 patent/US20220042022A1/en not_active Abandoned

Also Published As

Publication number	Publication date
TW201907008A (zh)	2019-02-16
AU2018277219A1 (en)	2019-12-19
KR20200015608A (ko)	2020-02-12
MX2019014187A (es)	2020-01-27
CR20190543A (es)	2020-02-10
PE20191845A1 (es)	2019-12-31
PH12019502636A1 (en)	2020-06-08
BR112019025290A2 (pt)	2020-06-23
CO2019013317A2 (es)	2020-01-17
US20220042022A1 (en)	2022-02-10
CA3062590A1 (fr)	2018-12-06
US20200157546A1 (en)	2020-05-21
US20190055564A1 (en)	2019-02-21
IL271039A (en)	2020-01-30
RU2019143004A (ru)	2021-07-09
CN110691849A (zh)	2020-01-14
JP2020521491A (ja)	2020-07-27
CL2019003337A1 (es)	2020-05-15
EP3630976A1 (fr)	2020-04-08
WO2018220034A1 (fr)	2018-12-06
JP7169995B2 (ja)	2022-11-11

Publication	Publication Date	Title
FR25C1001I2 (fr)	2026-01-02	Compositions d'anticorps pour le traitement de tumeurs
EP3607023C0 (fr)	2023-06-07	Solutions micellaires pour traitement de formations d'hydrocarbures
EP3334499A4 (fr)	2019-04-17	Conjugués bioactifs pour l'administration d'oligonucléotides
EP3679141C0 (fr)	2023-06-07	Méthodes et compositions pour inhiber l'expression de la ldha
MA47719A (fr)	2020-01-15	Esketamine pour le traitement de la dépression
PT3506909T (pt)	2022-08-16	Análogos de 4¿-fosfato e oligonucleótidos compreendendo os mesmos
EP3526328A4 (fr)	2020-05-27	Polythérapie pour l'inhibition de c3
EP3353328A4 (fr)	2019-06-12	Modulateurs de l'expression de kras
EP3402549A4 (fr)	2019-09-11	Compositions pour micro-aiguilles et méthodes d'utilisation de celles-ci
EP3431075A4 (fr)	2020-01-22	Forme galénique d'édaravone
IL290449A (en)	2022-04-01	Antibody-mediated neutralization of chikungunya virus
EP3325963A4 (fr)	2019-08-14	Amélioration de l'estimation de globules
EP3853365A4 (fr)	2022-06-08	Modulateurs de l'expression de pnpla3
MA53924A (fr)	2021-08-25	Modulateurs de l'expression d'apol1
IL269735A (en)	2019-11-28	Antisense oligonucleotides for the treatment of stargardt disease
EP3470052A4 (fr)	2020-02-26	Composition cosmétique pour les yeux
MA43570A (fr)	2018-11-14	Thérapie génique pour traiter l'hypercholestérolémie familiale
MA51795A (fr)	2020-12-16	Oligonucléotides pour moduler l'expression de tmem106b
EP3634426A4 (fr)	2021-04-07	Compositions pour le traitement d'une fibrose
EP3397288A4 (fr)	2019-09-11	Méthodes pour diminuer l'expression de l'ataxine-2
EP3541379A4 (fr)	2020-05-27	Compositions pour le traitement de l'hypertension
EP3403655A4 (fr)	2019-08-07	Composition pour augmenter l'expression de pgc-1
EP3424868A4 (fr)	2019-11-20	Mécanisme d'extension/contraction
MA53474A (fr)	2022-01-05	Distribution de lingettes
EP3733177A4 (fr)	2021-10-27	Composition pour la protection de la cornée